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Editor, 
Hidradenitis suppurativa (HS) has been associated with the occurrence of psychiatric 
disorders (PD) such as depression [1], anxiety [1], bipolar disorder [2] or schizophrenia [2]. A 
recent national register-based case-control study in Finland [2] showed that patients with 
HS had a higher risk of mental disorders than those with psoriasis. Women with HS 
displayed a greater risk of suicide [3]. In the present study, we aimed to evaluate the 
prevalence of PD within a cohort of Finnish patients with HS and compare whether the 
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phenotype and comorbidities of those patients would differ from those without PD. We 
reviewed retrospectively all the patients with HS diagnosis that attended a tertiary care 
hospital (Department of dermatology, Helsinki University Hospital, Finland) between 
January and December 2018. We collected for each patient the following: age, age at onset 
and at diagnosis, family history, smoking, comorbidities, Hurley stages, number of affected 
regions, and affected body sites. As the study relied on the centralized medical reports of 
our patients, including both university hospital and primary healthcare with no direct 
patient contact, no ethical committee statement was required. 
 
A total of 167 patients were included (97 women, mean age 38.4 years +/- 13.8).  The 
overall prevalence of patients with ≥1 PD was 35.9% (n=60). One patient could have several 
diagnoses. The median number of PD diagnoses per patient was 1.5 (range: 1-4).  Fifty-four 
patients (out of 60, 90%) had a PD diagnosed before HS diagnosis. Main diagnoses were 
depression (23.3%), anxiety (16.8%) and bipolar disorder (4.8%) (table 1). Table 2 
summarizes patients' main characteristics. Patients with PD were significantly younger 
(p=0.04), had an earlier onset of HS (p=0.03) and a higher mean BMI (p=0.02). The 
prevalence of PD was similar regarding gender, family history, smoking, cannabis, Hurley 
stages, number of affected regions (1-2 vs ≥3) and anatomic locations (except 
buttocks/perianal area, p=0.01 and breast for women, p=0.04). There was no difference 
regarding acne, cardio-vascular disorders (hypertension, arrhythmia, limb arteriopathy, 
stroke, gout), dyslipidemia, diabetes, hypothyroidism and inflammatory disorders. Patients 
with PD were more likely to have a BMI>25 (p=0.04), migraine headaches (p=0.03), asthma 
(p=0.04) and sinus pilonidalis (p=0.03). However, we did not find any significant association 
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with multivariate analysis including gender, age, smoking, overweight/obesity, sinus 
pilonidalis, asthma and migraine. 
 
The prevalence of PD and mental comorbidities was similar than the study by Huijala et al 
[2]. Finnish HS patients with PD were younger, more in overweight or obese and presented 
various comorbidities such as migraine or asthma compared to those without PD. PD have 
been associated in the literature with obesity [5], migraine [6] and asthma [7]. Here no 
specific comorbidity was significantly associated with PD in HS patients after performing 
multivariate analysis. Limitations of our study are those of a single-center retrospective 
study in a small cohort from a tertiary care center with bias of selection of the patients with 
more severe conditions. However, the strength of our study relies on the fact that we 
reviewed thoroughly the public medical records of the 167 patients, including psychiatric 
reports. PD diagnoses could vary with time illustrating the difficulties to have a clear-cut 
diagnosis. HS can affect deeply patients’ quality of life [8]. However, in our series, the 
diagnosis of PD preceded the diagnosis of HS in 90% of the cases. One medical report 
acknowledged clearly that depression was reactional to HS. Two patients had past history of 
suicide attempts before HS diagnosis. We could not rule out that some patients had HS 
symptoms at the time, especially as there is a long delay between onset and HS diagnosis in 
Finland [9]. Lastly, three had past history of depression or anxiety, but were symptom-free 
without treatment, and one patient took antidepressant without any medical explanation: 
we did not consider these four patients as presenting PD at inclusion in the study.  
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Acknowledging the limits of our study, HS patients with or without PD had rather similar 
demographics, smoking habits, comorbidities, HS severity and disease localization. We 
found that in 90% of the cases, PD preceded HS diagnosis. The reasons for the association 
between PD and HS remain open.     
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Table 1. Proportion of psychiatric disorders according to gender in our cohort of HS 
patients 
 Total 
n(%) 
Men 
n(%) 
Women 
n(%) 
 
Any 60 (35.9) 21 (30.0) 39 (40.2) NS 
Depression 39 (23.3) 15 (21.4) 24 (24.7) NS 
Anxiety 28 (16.8) 10 (14.3) 18 (18.5) NS 
Bipolar disorder 8 (4.8) 1 (1.4) 7 (7.2) NS 
Schizophrenia 6 (3.6) 4 (5.7) 2 (2.1) NS 
Hyperactivity 6 (3.6) - 6 (6.2) - 
Post-traumatic 
stress disorder 
2 (1.2) 1 (1.4) 1 (1.0) NS 
Anorexia 3 (1.8) - 3 (3.1) - 
Binge Eating 
Disorder 
4 (2.4) - 4 (4.1) - 
Mental 
retardation 
3 (1.8) 1 (1.4) 2 (2.1) NS 
Compulsive 
disorder 
1 (0.6) 1 (1.4) - - 
NS : not significant 
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Table 2. Characteristics of the HS patients with and without psychiatric diseases 
 Psychiatric conditions
 
 
No psychiatric 
conditions 
 
P<0.05 
Chi2 or Mann-
Whitney U test 
Total, n (%) 60 (35.9) 107 (64.1)
Gender  
Men, n/70 (%) 
Women, n/97 (%) 
21 (30) 
39 (40.2) 
49 (70)
58 (59.8) 
NS 
Age, years (SD)  
Mean age  34.9 (10.5) 40.4 (15.0) 0.04 
Mean age at diagnosis 29.6 (9.7) 36.5 (13.9) 0.005 
Mean age at first 
symptoms  
22.5 (8.8) 28.5 (12.8) 0.03  
Familial history of HS* 11/31 (35.5) 15/32 (46.9) NS 
Hurley**  
Hurley I 11/32 (34.4) 23/51 (45.1) NS 
Hurley II 16 (50.0) 17 (33.3)
Hurley III 5 (15.6) 11 (21.6)
Number of anatomic 
regions involved 
 
1-2 regions involved 13 (21.7) 27 (25.2) NS 
 ≥3 regions involved 47 (78.3) 80 (74.8)
Smoking  
Ever smokers 43/58 (74.1) 75/100 (75.0) NS 
Active smokers 30 (51.7) 52 (52.0) NS 
Cannabis 4/20 (20) 1/12 (8.3) NS 
BMI, mean (SD)  34.4 (8.9) 31.2 (6.7) 0.02 
Comorbidities 
Weight  
BMI 25-29 (Overweight 
and obesity) 
50 (83.3) 71 (66.3) 0.02 
 
BMI 30 (Obesity) 35 (58.3) 50 (46.7) NS 
Diabetes type 2 7 (11.7) 20 (17.9) NS 
Hypothyroidism 10 (16.7) 8 (7.4) NS 
Sleep apnea 12 (20.0) 10 (9.3) NS 
Asthma  13 (21.7) 11 (10.3) 0.04 
Miscellaneous  
Migraine 12 (20) 9 (8.4) 0.03 
Acne 17 (28.3) 29 (27.1) NS 
Sinus pilonidalis 13 (21.7) 10 (9.3) 0.03 
Hypertension 12 (20.0) 25 (23.4) NS 
Dyslipidemia 7 (11.7) 11 (10.2) NS 
Autoimmune and 
inflammatory 
disorders 
 
Psoriasis 5 (8.3) 8 (7.5) NS 
Inflammatory bowel 
disease*** 
- 7 (6.5) NS 
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Inflammatory joint 
disease (total)**** 
3 (5.0) 9 (8.4) NS 
Anatomic region of HS
Armpits 47/60 (78.3) 80/107 (74.8) NS 
Buttocks 40 (66.7) 50 (46.7) 0.01 
Groins/inguinal folds 47 (78.3) 82 (76.6) NS 
Inner tights 20 (33.3) 29 (27.1) NS 
Breast***** 23/39 (59.0) 22/58 (37.9) 0.04 
Genitalia 19/59 (32.2) 42 (39.2) NS 
Pubis 16 (26.7) 29 (24.3) NS 
NS: Not significant; SD: Standard Deviation
*Family history available for 63 patients
**32 vs. 51 patients 
***Includes Crohn’s disease and ulcerative colitis 
****Includes reactive, rheumatoid, psoriatic arthritis and spondyarthropathy  
*****only for women 
 
 
 
